See the DrugPatentWatch profile for rolapitant
What is US 8,552,191 (rolapitant)?
US 8,552,191 is a U.S. patent related to rolapitant, a drug candidate used as an NK1 (neurokinin-1) receptor antagonist for preventing chemotherapy-induced nausea and vomiting. The patent number you gave—US 8552191—corresponds to that U.S. patent family record in patent databases.
Who owns US 8,552,191 and what does it cover?
Ownership and claim scope depend on the specific assignee and the exact claim set shown in the official patent record. In practice, patents covering drug candidates like rolapitant typically cover one or more of the following:
- the compound itself (rolapitant and/or specific forms)
- pharmaceutical compositions (how the drug is formulated)
- synthesis or intermediates
- methods of use (for example, preventing nausea and vomiting in specific treatment settings)
To state the exact assignee and the exact protected subject matter, I’d need the specific patent-page text (title/assignee/abstract/claims) or a link from your preferred database (USPTO, Google Patents, Lens, etc.).
How long does the rolapitant patent last (and when does it expire)?
Patent life is driven by the filing date, any priority dates, and whether it received patent-term adjustments. In the U.S., a utility patent generally expires about 20 years from its earliest effective non-provisional filing date (subject to adjustments/changes). The exact expiration date for US 8,552,191 requires the priority/filing dates shown on the record.
Also, drug exclusivity can continue beyond the patent through FDA exclusivities (separate from the patent), depending on the approval pathway and exclusivity grants.
Is there a risk of invalidation or challenges to US 8,552,191?
Challenges are usually pursued through:
- post-grant review (depending on what stage the patent is in)
- litigation alleging invalidity and/or non-infringement
- design-around (developing a product/process that avoids the patent’s claims)
Whether US 8,552,191 has specific known challenges or disputes can be confirmed only by checking litigation and PTAB records for that patent number.
How does this patent relate to rolapitant brands and generic competition?
Whether and when other companies can market a competing version depends on:
- which patents are listed for the relevant FDA product (Orange Book listing rules)
- whether those patents expire or get invalidated
- whether a biosimilar/generic can use the FDA abbreviated pathway and carve-outs for patented indications
The linkage between US 8,552,191 and any specific marketed product requires matching the patent to its FDA listing(s).
What are next steps to get the exact answer for US 8,552,191?
If you paste any of the following, I can give a precise, claim-by-claim summary and an estimated/actual expiration date:
- a link to the US 8,552,191 record on Google Patents or USPTO
- the patent title and assignee from the record
- the abstract and the first independent claims
- the earliest priority date shown on the record
Sources
No sources were provided in your message, so I can’t cite specific details about US 8,552,191 (assignee, title, claims, dates, or expiration) yet. If you share a link or key text, I’ll respond with an exact, cited summary.